Announcement PDF Acrux Limited (ACR:ASX) | ACN 082 001 152 103-113 Stanley St, West Melbourne VIC, 3003 Australia +61 3 8379 0100 | info@acrux.com.au Acrux Limited (ACR:ASX) ASX Announcement 2 October 2026 Acrux receives $1.977 million R&D Tax Incentive Rebate for FY26 Melbourne, Australia; Acrux Limited (ASX:ACR)is pleased to announce it has received its FY26 R&D Tax Incentive rebate (‘RDTI’) from the Australian Tax Office (‘ATO’) totalling $1,977,223. After full repayment of principal and interest associated with the short term funding facility provided by Radium Capital, Acrux has received a net balance of $904,656. The RDTI is an Australian Federal Government program under which companies may receive cash rebates for eligible research and development expenditure. Authorised for release by the Board of Directors of Acrux Limited. For more information, please contact: CEO & Managing Director John Warmbrunn E: john.warmbrunn@acrux.com.au P: + 61 3 8379 0100 CFO & Company Secretary Joanna Johnson E: joanna.johnson@acrux.com.au P: + 61 3 8379 0100 Media Relations Julia Maguire The Capital Network E: julia@thecapitalnetwork.com.au P: + 61 2 7257 7338 2 About Acrux: Acrux Limited (ASX:ACR) is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Click here to sign up to our InvestorHub and keep up to date with company news and latest developments or for further information on Acrux Limited visit www.acrux.com.au END.